Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
M Nishino, K Suda, Y Kobayashi, S Ohara, T Fujino… - Lung Cancer, 2018 - Elsevier
Objectives Non-small cell lung cancers (NSCLCs) that harbor activating mutations for
epidermal growth factor receptor (EGFR) show remarkable initial response to EGFR-tyrosine
kinase inhibitors (TKIs), but inevitably acquire resistance, half of which are due to a T790 M
secondary mutation when first-generation (1 G) or 2 G EGFR-TKIs are used. Osimertinib, a 3
G EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance,
reportedly due to some tertiary EGFR mutations. However, the FLAURA trial showed the …
epidermal growth factor receptor (EGFR) show remarkable initial response to EGFR-tyrosine
kinase inhibitors (TKIs), but inevitably acquire resistance, half of which are due to a T790 M
secondary mutation when first-generation (1 G) or 2 G EGFR-TKIs are used. Osimertinib, a 3
G EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance,
reportedly due to some tertiary EGFR mutations. However, the FLAURA trial showed the …
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
西野将矢， ニシノマサヤ - 博士学位論文/本文(平成30 年度授与), 2019 - kindai.repo.nii.ac.jp
Objectives: Non-small cell lung cancers (NSCLCs) that harbor activating mutations for
epidermal growth factor receptor (EGFR) show remarkable initial response to EGFR-tyrosine
kinase inhibitors (TKIs), but inevitably acquire resistance, half of which are due to a T790M
secondary mutation when first-generation (1G) or 2G EGFR-TKIs are used. Osimertinib, a 3G
EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance,
reportedly due to some tertiary EGFR mutations. However, the FLAURA trial showed the …
epidermal growth factor receptor (EGFR) show remarkable initial response to EGFR-tyrosine
kinase inhibitors (TKIs), but inevitably acquire resistance, half of which are due to a T790M
secondary mutation when first-generation (1G) or 2G EGFR-TKIs are used. Osimertinib, a 3G
EGFR-TKI, is a standard of care in this situation, but eventually also evokes resistance,
reportedly due to some tertiary EGFR mutations. However, the FLAURA trial showed the …
以上显示的是最相近的搜索结果。 查看全部搜索结果